Airaksinen, Juhani

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

The optimal management of patients on oral anticoagulation undergoing coronary artery stenting: The 10th Anniversary Overview

Faxon, D., Airaksinen, J., Schlitt, A., Marìn, F., Bhatt, D., Lip, G., & Rubboli, A. (2014) · Thrombosis and Haemostasis

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 60

Increased pulse pressure is associated with reduced baroreflex sensitivity

Virtanen, R., Jula, A., Huikuri, H., Kuusela, T., Helenius, H., Ylitalo, A., Voipio-Pulkki, L.-M., Kauma, H., Kesäniemi, Y. A., & Airaksinen, J. (2004) · Journal of Human Hypertension

Heart Rate Variability and Autonomic ControlCardiovascular Health and Disease Prevention

Cited by 21